Libby Horter

Libby Horter

Auto-generated profile, based on publicly available information

Libby Horter

Division of Infectious Disease Readiness and Innovation, Centers for Disease Control and Prevention, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
HTHope M. Tiesman
Hope M. Tiesman
SHScott A. Hendricks
Scott A. Hendricks
DWDouglas M. Wiegand
Douglas M. Wiegand
BLBarbara Lopes-Cardozo
Barbara Lopes-Cardozo
CRCarol Y. Rao
Carol Y. Rao
RBRamona Byrkit
Ramona Byrkit

8 July 2021 in Drug Safety
Verified
Journal Article
Open access
PDF file
VHVeena Hoffman
Veena Hoffman
JHJesper Hallas
Jesper Hallas
MLMarie Linder
Marie Linder
AMAndrea V. Margulis
Andrea V. Margulis
BSBrandon T. Suehs
Brandon T. Suehs
JSJohn D. Seeger
John D. Seeger
Introduction During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder. Objective The purpose of this study was to compare incidence rates of adverse cardiovascular (CV) outcomes following mirabegron or antimuscarinic use. Methods We conducted an observational post-marketing safety study utilising real-world data. The study population was identified within five sources: Danish and Swedish National Registers, Clinical Practice Research Datalink (UK), Optum (USA) and Humana (USA). Episodes of time when patients were new users of mirabegron or antimuscarinics (October 2012–December 2018) were sourced from prescriptions and matched on propensity scores. Occurrences of major adverse cardiovascular events (MACE), acute myocardial infarction (AMI), stroke, CV mortality and all-cause mortality were identified. Outcome incidence rates and hazard ratios from Cox models were estimated. Results Overall, 152,026 mirabegron and 152,026 antimuscarinic episodes were matched. The population consisted of 63.1% women and 72.6% were ≥ 65 years old. There were no appreciable differences in the incidence rates of MACE, AMI or stroke between users of mirabegron and antimuscarinics. Incidence rates of CV mortality (hazard ratio 0.83, 95% confidence interval 0.73–0.95) and all-cause mortality (hazard ratio 0.80, 95% confidence interval 0.76–0.84) were no higher with mirabegron vs antimuscarinics. Results restricted to episodes at high risk for CV events or stratified by age (< 65 years, ≥ 65 years) or prior overactive bladder medication use were consistent with overall findings. Conclusions This large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.

1 November 2005 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
HKHarriet Mayanja Kizza
Harriet Mayanja Kizza
BRBenigno Rodriguez
Benigno Rodriguez
Miguel Quiñones-MateuMiguel Quiñones-Mateu
Miguel Quiñones-Mateu
MMMuneer Mirza
Muneer Mirza
HAHtin Lin Aung
Htin Lin Aung
ZTZahra Toossi
Zahra Toossi
Tuberculosis (TB) is the most common life-threatening infection in human immunodeficiency virus (HIV)-infected persons and frequently occurs before the onset of severe immunodeficiency. Development of TB is associated with increased HIV type 1 (HIV-1) viral load, a fall in CD4 lymphocyte counts, and increased mortality. The aim of this study was to examine how treatment of pulmonary TB affected HIV-1 activity in HIV-1/TB-coinfected subjects with CD4 cell counts of >100 cells/μl. HIV-1/TB-coinfected subjects were recruited in Kampala, Uganda, and were monitored over time. Based upon a significant (0.5 log10copies/ml) decrease in viral load by the end of treatment, two patient groups could be distinguished. Responders (n= 17) had more rapid resolution of anemia and pulmonary lesions on chest radiography during TB treatment. This group had a significant increase in viral load to levels not different from those at baseline 6 months after completion of TB treatment. HIV-1 viral load in nonresponders (n= 10) with TB treatment increased and at the 6 month follow-up was significantly higher than that at the time of diagnosis of TB. Compared to baseline levels, serum markers of macrophage activation including soluble CD14 decreased significantly by the end of TB treatment in responders but not in nonresponders. These data further define the impact of pulmonary TB on HIV-1 disease. HIV-1 replication during dual HIV-1/TB infection is not amenable to virologic control by treatment of TB alone. Concurrent institution of highly active antiretroviral treatment needs to be evaluated in patients dually infected with pulmonary TB and HIV-1.

16 July 2022 in Annals of Epidemiology
Verified
Journal Article
Open access
AKAhoua Kone
Ahoua Kone
LHLibby Horter
Libby Horter
CRCharles Rose
Charles Rose
CRCarol Y. Rao
Carol Y. Rao
DODiana Orquiola
Diana Orquiola
BLBarbara Lopes-Cardozo
Barbara Lopes-Cardozo
To evaluate the association between risk factors, mitigating factors, and adverse mental health outcomes among United States public health workers. Cross-sectional online survey data were collected March to April 2021. The survey was distributed to public health workers who worked in a state, tribal, local, or territorial public health department since March 2020. In total, 26,174 United States state and local public health workers completed the survey. Feeling isolated was a risk factor for anxiety (PR, 1.84; 95% CI, 1.74-1.95), depression (PR, 1.84; 95% CI, 1.75-1.94), post-traumatic stress disorder (PR, 1.50; 95% CI, 1.43-1.57), and suicidal ideation (PR, 3.23; 95% CI, 2.82-3.69). The ability to take time off was linked to fewer reported symptoms of anxiety (PR, 0.87; 95% CI, 0.83-0.90), depression (PR, 0.86; 95% CI, 0.83-0.89), post-traumatic stress disorder (PR, 0.84; 95% CI, 0.81-0.88), and suicidal ideation (PR, 0.84; 95% CI, 0.77-0.92). Since COVID-19 was declared a pandemic, respondents who felt isolated and alone were at an increased risk for adverse mental health outcomes. Findings from this study call for public health organizations to provide their workforce with services and resources to mitigate adverse mental health outcomes.

20 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
STShichao Tang
Shichao Tang
LHLibby Horter
Libby Horter
KBKarin Bosh
Karin Bosh
AKAhmed M. Kassem
Ahmed M. Kassem
EKEmily B. Kahn
Emily B. Kahn
CRCarol Y. Rao
Carol Y. Rao
Objective: During the COVID-19 pandemic, the unemployment rate in the United States peaked at 14.8% in April 2020. We examined patterns in unemployment following this peak in counties with rapid increases in COVID-19 incidence. Method: We used CDC aggregate county data to identify counties with rapid increases in COVID-19 incidence (rapid riser counties) during July 1–October 31, 2020. We used a linear regression model with fixed effect to calculate the change of unemployment rate difference in these counties, stratified by the county’s social vulnerability (an indicator compiled by CDC) in the two months before the rapid riser index month compared to the index month plus one month after the index month. Results: Among the 585 (19% of U.S. counties) rapid riser counties identified, the unemployment rate gap between the most and least socially vulnerable counties widened by 0.40 percentage point (p<0.01) after experiencing a rapid rise in COVID-19 incidence. Driving the gap were counties with lower socioeconomic status, with a higher percentage of people in racial and ethnic minority groups, and with limited English proficiency. Conclusion: The widened unemployment gap after COVID-19 incidence rapid rise between the most and least socially vulnerable counties suggests that it may take longer for socially and economically disadvantaged communities to recover. Loss of income and benefits due to unemployment could hinder behaviors that prevent spread of COVID-19 (e.g., seeking healthcare) and could impede response efforts including testing and vaccination. Addressing the social needs within these vulnerable communities could help support public health response measures.

2 December 2022 in Journal of Public Health Management & Practice
Verified
Journal Article
Open access
CLChristi Msc Lane-Barlow
Christi Msc Lane-Barlow
ITIsabel Thomas
Isabel Thomas
LHLibby Horter
Libby Horter
RFRachael Fleurence
Rachael Fleurence
JGJamilla DrPH Green
Jamilla DrPH Green
DVDiana Valencia
Diana Valencia
Context: Health departments (HDs) work on the front lines to ensure the health of their communities, providing a unique perspective to public health response activities. Say Yes! COVID Test (SYCT) is a US federally funded program providing free COVID-19 self-tests to communities with high COVID-19 transmission, low vaccination rates, and high social vulnerability. The collaboration with 9 HDs was key for the program distribution of 5.8 million COVID-19 self-tests between March 31 and November 30, 2021. Objective: The objective of this study was to gather qualitative in-depth information on the experiences of HDs with the SYCT program to better understand the successes and barriers to implementing community-focused self-testing programs. Design: Key informant (KI) interviews. Setting: Online interviews conducted between November and December 2021. Participants: Sixteen program leads representing 9 HDs were purposefully sampled as KIs. KIs completed 60-minute structured interviews conducted by one trained facilitator and recorded. Main Outcome Measures: Key themes and lessons learned were identified using grounded theory. Results: Based on perceptions of KIs, HDs that maximized community partnerships for test distribution were more certain that populations at a higher risk for COVID-19 were reached. Where the HD relied predominantly on direct-to-consumer distribution, KIs were less certain that communities at higher risk were served. Privacy and anonymity in testing were themes linked to higher perceived community acceptance. KIs reported that self-test demand and distribution levels increased during higher COVID-19 transmission levels. Conclusion: HDs that build bridges and engage with community partners and trusted leaders are better prepared to identify and link high-risk populations with health services and resources. When collaborating with trusted community organizations, KIs perceived that the SYCT program overcame barriers such as mistrust of government intervention and desire for privacy and motivated community members to utilize this resource to protect themselves against COVID-19.